Mucosis
Groningen
About Mucosis
Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection. Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $17.2M
- Last round: Series Unknown (Jan 2016)
- Website: mucosis.com
- Phone: +31508200050
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/mucosis-2443640 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.